<a href="https://www.fiercebiotech.com/biotech/abbvie-inks-715m-deal-chinese-biotech-haisco-two-acute-pain-assets" hreflang="en">AbbVie inks $745M deal with Chinese biotech Haisco for two acute pain assets</a>

The key learning here is that AbbVie's $30 million investment in Haisco Pharmaceutical Group's non-opioid pain treatments signals a strategic shift towards non-opioid pain management solutions. This move highlights the increasing focus on alternative pain therapies, which could be an area for potential investment or partnership opportunities, particularly in the context of addressing the opioid crisis.